Klinischer Fortschritt 2006: Endokrinologie

Literatur

• 1 Levine J A, Lanningham-Foster L M, McCrady S K. et al . Interindividual variation in posture allocation: possible role in human obesity.  Science. 2005;  307 584-586
• 2 Wadden T A, Berkowitz R I, Womble L G. et al . Randomized trial of lifestyle modification and pharmacotherapy for obesity.  N Engl J Med. 2005;  353 2111-2120
• 3 Van Gaal L F, Rissanen A M, Scheen A J, Ziegler O. RIO-Europe Study Group . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
• 4 Pi-Sunyer F X, Aronne L J, Heshmati H M, Devin J, Rosenstock J,. RIO-North America Study Group . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America.  JAMA. 2006;  295 761-775 , ; Erratum in: JAMA. 2006 Mar 15;295:1252.
• 5 Donnez J, Dolmans M M, Demylle D. et al . Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.  Lancet. 2004;  364 1405-1410
• 6 Silber S J, Lenahan K M, Levine D J. et al . Ovarian transplantation between monozygotic twins discordant for premature ovarian failure.  N Engl J Med. 2005;  353 58-63
• 7 Alexander E K, Marqusee E, Lawrence J. et al. . Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.  N Engl J Med. 2004;  351 241-249
• 8 Centanni M, Gargano L, Canettieri G. et al . Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.  N Engl J Med. 2006;  354 1787-1795
• 9 Ayuk J, Clayton R N, Holder G. et al. . Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.  J Clin Endocrinol Metab. 2004;  89 1613-1617
• 10 Feenstra J, de Herder W W, ten Have S M. et al . Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.  Lancet. 2005;  365 1644-1646
• 11 Valkema R, Pauwels S. et al . Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.  Semin Nucl Med. 2006;  36 147-156
• 12 Kwekkeboom D J, Teunissen J J, Bakker W H. et al . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.  J Clin Oncol. 2005;  23 54-62